[7-valent conjugate Pneumococcal vaccine and nasopharyngeal cavity]

7-valent conjugate pneumococcal vaccine is effective for preventing invasive pneumococcal diseases in childhood. The present serotype formulation of the conjugate Pneumococcal Vaccine is effective for preventing 75-90% of the invasive pneumococcal disease cases, depending of the vaccine-serotypes distribution in the several countries. Recent studies, carried out in the north-american context, show that mass vaccination campaign by 7-valent conjugate Pneumococcal Vaccine in childhood, reduce, in vaccinated subjects, the nasopharyngeal colonization by vaccine-serotypes, that are much more joined to antibacterial resistance. This implies non only an active and specific protection for vaccinated, but also for family and community contacts, children and adults. This interesting results, need to be confirmed also in european countries, open a new view for a wider pharmacoeconomic evaluation of the 7-valent conjugate Pneumococcal Vaccine in childhood.